PHARMACEUTICAL IP

Evolve Insights

Welcome to Evolve Insights!

Evolve Insights is your go-to source for expert analysis and strategic perspectives on pharmaceutical IP.

  • Read our Articles for the latest pharma IP news and analysis. Many of our articles were originally published on IPKat.
  • Register for our upcoming live Webinars and watch our previous webinars on-demand.
  • Subscribe to our newsletter to stay up to date.

Do you have questions about how the latest developments in IP might impact you? Our team of experts would love to hear from you.

Latest articles

All articles

G 1/25 (description amendments) amicus curiae: The battle lines are drawn

If you want to start an argument amongst European patent attorneys, just mention description amendments. As the comments on this and other blogs attest, adaptation of the description is a highly divisive issue and the debate can get decidedly heated (with our US colleagues looking on with bemusement).

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic invention.

Non-reproducible products can be the closest prior art (T 1719/21)

G 1/23 establishes that products made available to the public are prior art in Europe, regardless of reproducibility. While this simplifies novelty, focusing strictly on disclosure dates, it complicates inventive step assessments. Notably, T 1719/21 questions whether these non-reproducible products can serve as the “closest prior art” in the EPO’s problem-solution approach.

Webinars

All webinars
  • On-demand

Unlocking the potential of cell & gene therapies with effective IP strategy

Recorded on: July 11, 2025
Discover how to transform ground-breaking cell & gene therapy science into commercial success with robust IP strategies.

Stay connected

Get the latest insights, news, and expert analysis on pharmaceutical IP delivered straight to your inbox.
Subscribe for updates